Lars Weidolf

3.8k citations

61 papers · 3.1k indexed · 1 hit paper · h-index 28

Impact in

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
Gastroenterology top 1%
- Gastroesophageal reflux and treatments

Papers in ⓘ

Pharmacology 32
- Pharmacogenetics and Drug Metabolism 29
- Drug-Induced Hepatotoxicity and Protection 8
- Plant-based Medicinal Research 5
Molecular Biology 15

Co-authors: Tommy B. Andersson (5 shared papers)Ulrik Jurva (11 shared papers)Xueqing Li (10 shared papers)Tommy Andersson (4 shared papers)Emre M. Isin (7 shared papers)Jack D. Henion (5 shared papers)Andries P. Bruins (2 shared papers)Richard A. Thompson (5 shared papers)
Journals: Drug Metabolism and Disposition (16 papers)Rapid Communications in Mass Spectrometry (5 papers)Chemical Research in Toxicology (5 papers)Xenobiotica (4 papers)Journal of Pharmacology and Experimental Therapeutics (2 papers)
Partner nations: Sweden United Kingdom United States

In The Last Decade

Lars Weidolf

59 papers receiving 2.9k citations

Hit Papers

align trajectories log scale

COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES 2004 · 495 citations

Peers

Countries citing papers authored by Lars Weidolf

Since Specialization

Citations

This map shows the geographic impact of Lars Weidolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Weidolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Weidolf more than expected).

Fields of papers citing papers by Lars Weidolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Weidolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Weidolf. The network helps show where Lars Weidolf may publish in the future.

Co-authors

The 25 scholars most cited alongside Lars Weidolf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lars Weidolf Line = papers co-authored together Lars Weidolf links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	COMPARISON OF INHIBITORY EFFECTS OF THE PROTON PUMP-INHIBITING DRUGS OMEPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE, PANTOPRAZOLE, AND RABEPRAZOLE ON HUMAN CYTOCHROME P450 ACTIVITIES Drug Metabolism and Disposition ·Xueqing Li, Tommy B. Andersson, Marie M. Ahlström, Lars Weidolf Hit paper breakdown →	2004	495
2	Use of Radiolabeled Compounds in Drug Metabolism and Pharmacokinetic Studies Chemical Research in Toxicology ·Emre M. Isin, Charles S. Elmore, Göran N. Nilsson, Richard A. Thompson, Lars Weidolf	2012	236
3	Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes Drug Metabolism and Disposition ·Angela Äbelö, Tommy B. Andersson, Madeleine Antonsson, Anna Knuts Naudot, Inger Skånberg, Lars Weidolf	2000	224
4	Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole Clinical Pharmacokinetics ·Tommy Andersson, Mohammed Hassan‐Alin, Gunnar Hasselgren, Kerstin R hss, Lars Weidolf	2001	196
5	Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions Rapid Communications in Mass Spectrometry ·Ulrik Jurva, Håkan Wikström, Lars Weidolf, Andries P. Bruins	2003	178
6	In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs Chemical Research in Toxicology ·Richard A. Thompson, Emre M. Isin, Yan Li, Lars Weidolf, Ken Page, Ian D. Wilson, Steve Swallow, Brian Middleton, Simone H. Stahl, Alison J. Foster, Hugues Dolgos, Richard Weaver, J. Gerry Kenna	2012	153
7	Mimicry of phase I drug metabolism – novel methods for metabolite characterization and synthesis Rapid Communications in Mass Spectrometry ·Tove Johansson, Lars Weidolf, Ulrik Jurva	2007	113
8	Determination of sulfonated azo dyes by liquid chromatography/atmospheric pressure ionization mass spectrometry Analytical Chemistry ·Andries P. Bruins, Lars Weidolf, Jack D. Henion, William L. Budde	1987	110
9	State-of-the-art Tools for Computational Site of Metabolism Predictions: Comparative Analysis, Mechanistical Insights, and Future Applications Drug Metabolism Reviews ·Lovisa Afzelius, Catrin Hasselgren Arnby, Anders Broo, Lars Carlsson, Christine Isaksson, Ulrik Jurva, B. K. Charlotte Kjellander, Karin Kolmodin, Kristina Nilsson, Florian Raubacher, Lars Weidolf	2007	88
10	Determination of boldenone sulfoconjugate and related steroid sulfates in equine urine by high-performance liquid chromatography/tandem mass spectrometry Journal of Mass Spectrometry ·Lars Weidolf, Edgar D. Lee, Jack D. Henion	1988	87
11	Stereoselective Disposition of Proton??Pump Inhibitors Clinical Drug Investigation ·Tommy Andersson, Lars Weidolf	2008	76
12	Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development Chemico-Biological Interactions ·Richard A. Thompson, Emre M. Isin, Yan Li, Richard Weaver, Lars Weidolf, Ian D. Wilson, Alf Claesson, Ken Page, Hugues Dolgos, J. Gerry Kenna	2010	69
13	Cytochrome P450-mediated activation of the fragrance compound geraniol forms potent contact allergens Toxicology and Applied Pharmacology ·Lina Hagvall, Jens Malte Baron, Anna Börje, Lars Weidolf, Hans F. Merk, Ann‐Therése Karlberg	2008	65
14	In Vitro Metabolism of Haloperidol and Sila-Haloperidol: New Metabolic Pathways Resulting from Carbon/Silicon Exchange Drug Metabolism and Disposition ·Tove Johansson, Lars Weidolf, Friedrich Popp, Reinhold Tacke, Ulrik Jurva	2009	63
15	Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure Elucidation Using Electrochemistry, Mass Spectrometry, and NMR Drug Metabolism and Disposition ·Tove Johansson, Ulrik Jurva, Gunnar Grönberg, Lars Weidolf, Collen Masimirembwa	2008	55
16	In Vitro Evaluation of Major In Vivo Drug Metabolic Pathways Using Primary Human Hepatocytes and HepaRG Cells in Suspension and a Dynamic Three-Dimensional Bioreactor System Journal of Pharmacology and Experimental Therapeutics ·Malin Darnell, Maria Ulvestad, Ewa Ellis, Lars Weidolf, Tommy B. Andersson	2012	53
17	Metabolism of Xenobiotic Carboxylic Acids: Focus on Coenzyme A Conjugation, Reactivity, and Interference with Lipid Metabolism Chemical Research in Toxicology ·Malin Darnell, Lars Weidolf	2013	48
18	Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development Drug Discovery Today ·Shalini Andersson, Madeleine Antonsson, Marie Elebring, Rasmus Jansson‐Löfmark, Lars Weidolf	2018	46
19	Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes Chemical Research in Toxicology ·Malin Darnell, Katarina Breitholtz, Emre M. Isin, Ulrik Jurva, Lars Weidolf	2015	44
20	Absorption, Distribution and Elimination of Felodipine in Man Drugs ·B. Edgar, K J Hoffmann, Per Lundborg, C G Regårdh, Ola Rönn, Lars Weidolf	1985	42

About Lars Weidolf

Lars Weidolf is a scholar working on Pharmacology, Molecular Biology, Spectroscopy, Oncology and Computational Theory and Mathematics, having authored 61 papers that have together received 3.1k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (29 papers), Analytical Chemistry and Chromatography (12 papers), Drug Transport and Resistance Mechanisms (12 papers), Drug-Induced Hepatotoxicity and Protection (8 papers), Computational Drug Discovery Methods (7 papers), Mass Spectrometry Techniques and Applications (6 papers), Plant-based Medicinal Research (5 papers) and Eicosanoids and Hypertension Pharmacology (5 papers). The work is most often cited by research in Pharmacology (923 citations), Gastroenterology (359 citations), Pharmaceutical Science (284 citations), Spectroscopy (587 citations) and Analytical Chemistry (262 citations). Lars Weidolf has collaborated with scholars based in Sweden, United Kingdom and United States. Frequent co-authors include Tommy B. Andersson, Ulrik Jurva, Xueqing Li, Tommy Andersson, Emre M. Isin, Jack D. Henion, Andries P. Bruins, Richard A. Thompson, Tove Johansson and Madeleine Antonsson. Their work appears in journals such as Drug Metabolism and Disposition, Rapid Communications in Mass Spectrometry, Chemical Research in Toxicology, Xenobiotica and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact